

April 6, 2026

Price (close on April 3, 2026)
\$4.47

Rating
Buy-Extended

12- Month Target Price
\$9.00

Andrew White, CFA
Research@EmergingGrowth.com

About the Company


SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers via a franchise model in Japan, Vietnam, Thailand, Singapore and the United States. Revenue is sourced from five segments: Franchising, Procurement, Management Services, Rental, and Other. The Company was founded in 2000.

52-Week Range	\$2.97 - \$5.75
Shares Outstanding	103 mil
Insider/Institutional	87%/0%
Public Float	\$38 mil
Market Capitalization	\$458 mil
Total Debt	\$43 mil
Debt / Equity	16%
ROE (TTM)	26%
Book Value / Share	\$2.57
Daily Volume (90-day)	31,900
Fwd. Div. & Yield	--

Return to Growth in 2026: Long-term accomplished founder and management have shepherded SBC from a solo clinic in 2000 to become a global cosmetic treatment center franchiser and cash generation machine with little debt. Near-term revenue growth decline in 2025 on near-term pricing pressures (reflecting increased market competition pressure) is expected to end in early-2026. Looking through the valley then sees the Company growing again this year with additional prospects for global M&A in addition to Japanese M&A as well as AI and longevity initiatives. SBC remains heavily undervalued traditionally and via a DCF analysis (especially net of ample Net Cash). We are bullish and **reiterate a Buy-Extended rating with a \$9.00 price target.**

FYE Dec Revenue (\$ mil.)	FY 2024A	FY 2025A		FY 2026E	
	ACTUAL	CURRENT	FORMER	CURRENT	FORMER
Q1 Mar	\$54.8A	\$47.3A	\$47.3A	\$43.5E	\$43.4E
Q2 Jun	\$53.1A	\$43.4A	\$43.4A	\$44.8E	\$48.8E
Q3 Sep	\$53.1A	\$43.4A	\$43.4A	\$46.2E	\$48.8E
Q4 Dec	\$44.4A	\$39.6A	\$43.4E	\$47.6E	\$48.8E
Year	\$205.4A	\$173.6A	\$177.4E	\$182.1E	\$189.7E
Change	6%	(16)%	(14)%	5%	7%

FYE Dec EPS (\$)	FY 2024A	FY 2025A		FY 2026E	
	ACTUAL	CURRENT	FORMER	CURRENT	FORMER
Q1 Mar	\$0.20A	\$0.21A	\$0.21A	\$0.12E	\$0.10E
Q2 Jun	\$0.20A	\$0.02A	\$0.02A	\$0.12E	\$0.13E
Q3 Sep	\$0.03A	\$0.12A	\$0.12A	\$0.13E	\$0.13E
Q4 Dec	\$0.06A	\$0.14A	\$0.10E	\$0.14E	\$0.13E
Year	\$0.48A	\$0.50A	\$0.46E	\$0.50E	\$0.49E
P/E Ratio	9.3	9.0	9.7	8.9	9.1



Q4:25 Financial Performance

- Revenue remains under yoy pressure, but revenue and operating profit are expected to recover in 2026. Cash remains strong.
- Dominant franchise position in the local Japanese industry with underlying volume growth, though near-term sales pricing pressure
- 25-year track record with the founder and management and M&A (e.g., AHH in Singapore, Orange Twist in the United States)
- Heavily discounted shares with increasing steps by management to improve liquidity in share trading

Key Risks

- Potentially longer-than-expected revenue rebound expected on increased competition, though importantly not being seen in volumes.
- Japanese market and franchisee concentration presents diversifiable risks – less of an issue with future global M&A
- Limited international experience in SE Asia and U.S. markets that are targets for global M&A (judicious in approach then)
- Relatively small share free float hampers liquidity, though steps are being taken to change this reality

Investment Thesis

SBC underwent financial recapitalization in Q3:24, during which the holding company Pono Capital Two, Inc. (“Pono”) merged the business lines of prior SBC businesses and renamed itself SBC Medical Group Holdings, Inc. Collectively, the Company is now the largest player in Japanese cosmetic treatment with an estimated 25% market share in the highly-fragmented industry in which the Company currently generates 99% of revenue.

The Company operates reasonable prices/a high turnover model (e.g., Shonan Beauty dermatology, Gorilla Clinic) as well as higher-growth/higher-margin dermatological aesthetics (e.g., JUN Clinic, NEO Skin Clinic), including an increasing focus on male customers. SBC has also expanded internationally with management recruitment, acquisition of AHH in Singapore, a partnership with BLEZ ASIA in Thailand, and an equity investment/partnership with Orange Twist in the United States.

SBC clinics have continued to grow organically and via acquisitions (i.e., +34 total SBC clinics or +14% in the last 12 months to reach a total of 283 clinics). The goal is to grow from 283 clinics currently to 1,000 in nine years, implying a 15% long-term CAGR in clinics. The Company now reports 6.6 million visits annually (which is unmatched in Japan) and a 72% repeat rate. Average revenue per visit is also trending up to \$316 in Q4:25 (+11% from Q4:24), despite fierce competition.

Since mid-2024 (around the time of Q3:24 recapitalization), SBC shares have declined (70%), reflecting revenue slowdown in later 2024-2025 due to increased local market competition. Indeed, a Q2:25 change in franchise fee pricing structure reduced quarterly revenue over the following three quarters from a \$45-\$55 million run rate in 2024 to a \$40-\$45 million run rate currently. It is expected that revenue generation will remain at the ~\$45 million level growing steadily through 2026 (+5% overall during the year) after which SBC should return to its historical +10% to +15% CAGR historical range. Moreover, the Company has launched two new major initiatives: AI-driven operations (i.e., customer experience, staffing) and Wellness 2.0/Longevity (inspired by models in the U.S.) which underscore future revenue and expense control prospects.

With growing underlying procedure volume, 70%-75% gross margins, and operating expense control (reflecting the franchise model), SBC is a cash-generation machine. As of the end of Q4:25, the Company carried \$164 million in cash on the balance sheet (out of \$231 million in total current assets). Net of limited \$43 million short and long-term commercial bank loans (i.e., low-APR borrowing in Japan), Net Current Assets are approximately 50% of SBC’s total assets or ~40% of its current fully-diluted \$460 million market capitalization (~25% in Net Cash alone). In effect then, the Net Cash price of SBC shares is about \$3.30 per share (or ~\$2.60 Net of Current Assets), not the listed \$4.47 per share price as of April 3, 2026.

Accordingly, SBC is heavily discounted with best yet to come on both domestic Japanese and global expansion, post-2025 treatment pricing change. Moreover, to improve trading liquidity, SBC has also taken several steps: e.g., became a Russell 3000 company (June 2025) and executed a share buyback in 2025. The Company is also contemplating the potential creation of a dividend program, partial liquidation of its founder’s share ownership, and perhaps an additional share issuance to support global M&A activity. **We are bullish and reiterate a Buy-Extended rating with a \$9.00 price target.**

Q4:25 Financial Performance

SBC’s revenue declined (11%) yoy in Q4:25 to \$39.6 million versus \$44.4 million in Q4:24 primarily reflecting the impact of an early-2025 franchising fee reduction. Underlying volumes increased as 34 more locations were added yoy (i.e., franchise locations were 283 as of end of 2025) and customer number increased +12% yoy (i.e., 6.6 million customers in the twelve months ended December 31, 2025 with a repeat rate of 72%). Management estimates that total revenue will now begin to regrow +5% overall in 2026, as the effect of the revised fee structure for clinic services completes full absorption.

Gross profit in Q4:25 was \$28.9 million compared to \$33.9 million in Q4:24 reflecting the decline in Franchising and Management Services revenue. Sequentially, gross profit basically stabilized versus \$30.6 million in Q3:25 as gross margin increase partially offset revenue decline. Operating profit in Q4:25 rose to \$12.9 million compared to \$4.7 million in Q4:24 due to the absence of a 2024 patent-related goodwill write-down. Sequentially, operating profit decreased from \$15.9 million in Q3:25. SBC’s Net Income from Continuing Operations in Q4:25 rose strongly to \$14.2 million versus \$6.5 million in Q4:24 on lack of goodwill write-down. Sequentially, Net Income from Continuing Operations also rose from \$12.8 million in Q3:25. Adjusted EBITDA, a non-GAAP measure, was \$18.0 million in Q4:25 versus \$7.8 million in Q4:24 and \$17.1 million in

Q3:25. EPS rose strongly to \$0.14/share from \$0.06 in Q4:24 and \$0.12 sequentially in Q3:25. Cash remained plentiful at \$164 million while debt load remained low at 16% Debt/Book Equity.

EPS Guidance, Estimates, and Valuation

SBC management estimates that revenue growth will be muted in Q1:26 on lingering 2025 price changes, but full-year 2026 should see a progressive return to +5% revenue growth while gross and operating margins remain at (or increase from) current levels. This expectation implies a healthy recovery of operating profit in 2026 versus a difficult 2025 year. +10% to +15% CAGR revenue growth thereafter is expected to return reflecting both domestic return to organic growth as well as select M&A activity in Japan, Southeast Asia, and the United States. Importantly, we step-down revenue growth by (1)%/year from 2028-2035. Gross margin is expected at ~70% while Operating margin is expected to rise back to ~40%.

We traditionally value companies using a blend of peer group relative valuation multiples and a Discounted Cash Flow (DCF) model. However, SBC is a unique Company in the niche Japanese/global cosmetic treatment industry. Most of its industry is fragmented, and there are few publicly-traded true comparables. The closest peer in the United States is AIRS, which has a lower headline Price/Sales ratio commensurate with being unprofitable/low-growth with a higher debt-load.

So, we currently downplay relative valuation analysis. That said, even a cursory glance at SBC’s Price/Earnings, Price/Sales, and PEG ratios make it clear that SBC is undervalued (especially net of Cash or Current Assets). Moreover, the Company’s considerable Net Cash on the balance sheet (~25% of market value as of 4/3/2026 or ~40% Net Current Assets/market value) calls for Discounted Cash Flow (“DCF”) analysis. Exhibit 1 below summarizes peer group. Historical and proforma forecast financial statements as well as a DCF model are included on pages six through ten of this report.

Exhibit 1: SBC Medical Group Holdings, Inc. Peer Group Multiples and Price Target

Company Name	Ticker	Price (11/21/24)	Shares (MM)	Market Cap (\$millions)	Trailing Price/Sales	Forward P/Sales	Trailing P/E	Forward P/E	Forward PEG
Airsulpt Tech	AIRS	\$3.17	70.6	\$224	1.5	1.4	NM	NM	NM
Industry Averages (ex: negatives)				\$224	1.5	1.4	NM	NM	NM
SBC Medical Group Holdings, Inc.	SBC	\$4.47	102.6	\$459	2.6	2.5	9.0	8.9	0.7
SBC (Adj. for Net Cash on Q4:25 Balance Sheet)	SBC	\$3.29	102.6	\$459	1.9	1.9	6.6	6.6	0.5
SBC (Adj. for Net Current Assets on Q4:25 Balance Sheet)	SBC	\$2.63	102.6	\$459	1.6	1.5	5.3	5.2	0.4
Discounted Cash Flow Estimate		\$9.46							

Source: Emerging Growth Research and SBC Medical Group Holdings, Inc.

Our DCF model uses financial statement estimates for 2026 and projections for years thereafter. We focus on Free Cash Flow, which we expect to resume +12.5% CAGR expansion in 2027 (mid-point of +10% to +15% range), with rate of growth declining (1)% each year to a terminal 3% growth rate achieved ten years from now in 2035. Operating margin is expected to remain at an average 40% over the period covered. We believe these estimates are conservative.

We discount estimated annual free cash flows by a 10.7% WACC, inclusive of risk premiums for the risk-free-rate, equity market, trading liquidity, and small-cap risk. Our DCF model produces a \$9.46/share present value of equity (inclusive of cash and warrants), which we round down to \$9.00. Sensitivity analysis (for different terminal growth and discount rates) indicates a min/max share price-estimate range of \$7.45 - \$12.55 which adds confidence in our price target estimate.

Our price target is materially higher than the current \$4.47 price of SBC shares as of April 3, 2026. Investors significantly sold off SBC shares in 2024, but shares stabilized in 2025 on operating earnings steadiness/re-testing of Q1:25 lows. We focus on the future. If management is able to continue stabilization of operating profit and regrow its top-line in 2026, share price upside is considerable. **We reiterate a Buy-Extended rating and a \$9.00 price target.**

Important Disclosures

Emerging Growth.com ("EG") is a publisher and distributor of branded investment research reports provided by Emerging Growth Research LLC ("EGR Report") focused on both public and private companies. This report was prepared for institutional and professional investors ONLY, and it is also known as Company Sponsored Research ("CSR"). Collectively, however ("EGR Report(s)").

Be advised that this EGR Report is being provided by Emerging Growth Research LLC (EGR) solely for informational purposes, is not the opinion of EG, should not be construed as an offer or solicitation to buy or sell securities, and should not be considered in any decision to buy or sell any security mentioned within the EGR Reports. All information contained in the EGR Report as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive, timely, or correct. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks. Because EGR is compensated as detailed herein and EG receives Licensing fees from EGR, as also detailed herein, EG and EGR have a conflict of interest and strongly urge you to consult your own independent financial, investment, tax, and legal advisors prior to purchasing or selling any securities mentioned herein.

The analyst that has prepared and is responsible for the content of this report has stated that neither he/she, nor any of his/her associates both professional and personal, to the best of his/her knowledge have no personal or professional relationship with any of the companies or principals of any companies mentioned within, other than providing services that EGR may offer.

EGR is being compensated by the subject Company of this report. EGR was paid thirty-four thousand and two hundred dollars and does not expect to receive an additional amount over the following three months. EGR may have also received additional past compensation, EGR may receive future compensation, and EG may receive compensation for additional services such as presenting on the Emerging Growth Conference or investor or public relations services, details about which can be found in the full disclosure, here: <https://EmergingGrowth.com/sbc-egr-report-disclosure/>.

It is the intent of EGR to provide continuing coverage on a quarterly basis, or otherwise for the subject Company of this report; however, EGR and EG will not notify readers of this report if coverage by EGR, for any reason is terminated.

The reader or user of this content agrees that neither EGR and / or EG nor the analysts, directors, officers, employees, representatives, independent contractors, agents or affiliates of EGR and EG shall be liable or held liable for any omissions, errors, or inaccuracies, regardless of cause, foreseeability, or the lack of timeliness of this or any of our other reports to users. This lack of liability extends to direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, losses, lost income, lost profit, or opportunity costs.

Again, all information contained herein should be independently verified by your own research and your own independent financial, investment, tax, and legal advisors prior to purchasing or selling any securities mentioned herein.

In addition to the specific disclosures mentioned herein, you are encouraged to read our general disclosure here: EmergingGrowth.com/Disclosure.

Rating Definitions

Buy, 30% or greater price appreciation in the next 12 months.

Buy-Extended, near-term EPS and/or revenue horizon is challenging with strong long-term appreciation possibility.

Buy-Emerging, initial stages with low revenue and the potential for large returns with higher risk and volatility.


Hold, perform similar to market.

Sell, 30% or more decline in the next 12 months.

© Copyright 2026 Emerging Growth Research LLC

No part of this material may be copied, photocopied, or duplicated in any form by any means or redistributed without the prior written consent of Emerging Growth Research LLC.

5-Year Chart



SBC Medical Group Holdings, Inc.
 Nasdaq: SBC
 Quarterly Results & Estimates
 \$ in Millions

	2023 Actual	2024 Actual	2025 Actual					2026 Estimated				
	Fiscal 2023A	Fiscal 2024A	1QA Mar-25	2QA Jun-25	3QA Sep-25	4QA Dec-25	Fiscal 2025A	1QE Mar-26	2QE Jun-26	3QE Sep-26	4QE Dec-26	Fiscal 2026E
Revenues												
Franchising	\$ 42.10	\$ 61.03	\$ 15.72	\$ 10.01	\$ 9.93	\$ 10.29	\$ 45.94	N/A	N/A	N/A	N/A	N/A
Procurement	\$ 53.19	\$ 54.81	\$ 14.33	\$ 15.76	\$ 13.41	\$ 12.56	\$ 56.05	N/A	N/A	N/A	N/A	N/A
Management Services	\$ 72.28	\$ 53.11	\$ 8.73	\$ 5.14	\$ 9.46	\$ 6.30	\$ 29.63	N/A	N/A	N/A	N/A	N/A
Rental Services	\$ 7.34	\$ 16.14	\$ 5.64	\$ 6.85	\$ 6.22	\$ 4.32	\$ 23.03	N/A	N/A	N/A	N/A	N/A
Other	\$ 18.63	\$ 20.31	\$ 2.91	\$ 5.61	\$ 4.34	\$ 6.10	\$ 18.95	N/A	N/A	N/A	N/A	N/A
Elimination of intercompany transactions	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	N/A	N/A	N/A	N/A	N/A
Total Revenues	\$ 193.54	\$ 205.42	\$ 47.33	\$ 43.36	\$ 43.35	\$ 39.57	\$ 173.61	\$ 43.52	\$ 44.83	\$ 46.17	\$ 47.56	\$ 182.08
YOY Revenue Growth (%)	N/A	6.1%	-13.6%	-18.3%	-18.3%	-10.9%	-15.6%	-8.0%	3.4%	6.5%	20.2%	4.9%
Cost of Revenues	\$ 56.24	\$ 49.37	\$ 9.60	\$ 13.35	\$ 12.74	\$ 10.64	\$ 46.32	\$ 10.88	\$ 11.21	\$ 11.54	\$ 11.89	\$ 45.52
Cost of Revenues/Sales (%)	29.1%	24.0%	20.3%	30.8%	29.4%	26.9%	26.7%	25.0%	25.0%	25.0%	25.0%	25.0%
Gross Profit	\$ 137.31	\$ 156.05	\$ 37.73	\$ 30.01	\$ 30.61	\$ 28.93	\$ 127.28	\$ 32.64	\$ 33.62	\$ 34.63	\$ 35.67	\$ 136.56
Gross Margin	70.9%	76.0%	79.7%	69.2%	70.6%	73.1%	73.3%	75.0%	75.0%	75.0%	75.0%	75.0%
SG&A	\$ 66.24	\$ 70.69	\$ 13.53	\$ 15.46	\$ 14.73	\$ 16.08	\$ 59.80	\$ 15.32	\$ 15.32	\$ 15.32	\$ 15.32	\$ 61.29
% of sales	34.2%	34.4%	28.6%	35.6%	34.0%	40.6%	34.4%	35.2%	34.2%	33.2%	32.2%	33.7%
Depreciation, depletion & amortization	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
% of sales	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Impairment of goodwill	\$ -	\$ 15.06	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain on disposal of assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 0.41	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of other long-lived assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total Operating Expenses	\$ 66.64	\$ 85.75	\$ 13.53	\$ 15.46	\$ 14.73	\$ 16.08	\$ 59.80	\$ 15.32	\$ 15.32	\$ 15.32	\$ 15.32	\$ 61.29
% of sales	34.4%	41.7%	28.6%	35.6%	34.0%	40.6%	34.4%	35.2%	34.2%	33.2%	32.2%	33.7%
Operating Profit	\$ 70.66	\$ 70.30	\$ 24.20	\$ 14.56	\$ 15.88	\$ 12.85	\$ 67.49	\$ 17.32	\$ 18.30	\$ 19.31	\$ 20.34	\$ 75.27
Operating Margin	36.5%	34.2%	51.1%	33.6%	36.6%	32.5%	38.9%	39.8%	40.8%	41.8%	42.8%	41.3%
Interest expense and financing charges, net	\$ (0.05)	\$ (0.03)	\$ (0.01)	\$ (0.03)	\$ (0.05)	\$ (0.06)	\$ (0.16)	\$ (0.06)	\$ (0.06)	\$ (0.06)	\$ (0.06)	\$ (0.22)
Interest expense and financing charges, net - related parties	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other income, net	\$ 3.62	\$ 4.81	\$ 7.20	\$ 0.03	\$ 0.15	\$ 3.18	\$ 10.57	\$ -	\$ -	\$ -	\$ -	\$ -
Other, net - related parties	\$ (0.66)	\$ (1.63)	\$ 0.06	\$ (1.02)	\$ 2.53	\$ 2.59	\$ 4.15	\$ 2.63	\$ 2.72	\$ 2.91	\$ 3.12	\$ 11.38
Pretax Income	\$ 73.58	\$ 73.46	\$ 31.45	\$ 13.54	\$ 18.51	\$ 18.57	\$ 82.07	\$ 19.89	\$ 20.96	\$ 22.16	\$ 23.40	\$ 86.43
Income Tax (benefit)	\$ 35.02	\$ 26.77	\$ 9.96	\$ 11.10	\$ 5.67	\$ 4.29	\$ 31.02	\$ 7.96	\$ 8.39	\$ 8.87	\$ 9.36	\$ 34.57
Effective tax rate	48%	36%	32%	82%	31%	23%	38%	40%	40%	40%	40%	40%
Income (Loss) attributable to minority interests	\$ (0.81)	\$ 0.08	\$ 0.01	\$ 0.02	\$ 0.01	\$ 0.08	\$ 0.12	\$ 0.08	\$ 0.08	\$ 0.08	\$ 0.08	\$ 0.32
GAAP Net Income from Continuing Operations	\$ 39.37	\$ 46.61	\$ 21.48	\$ 2.43	\$ 12.82	\$ 14.20	\$ 50.93	\$ 11.86	\$ 12.50	\$ 13.22	\$ 13.96	\$ 51.54
Foreign currency adjustment	\$ 12.89	\$ 16.56	\$ (9.81)	\$ (8.62)	\$ 6.79	\$ 14.59	\$ 2.95	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 0.01	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Income (Loss) attributable to minority interests	\$ (0.95)	\$ 0.12	\$ (0.04)	\$ 0.18	\$ 0.01	\$ (0.01)	\$ 0.11	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.05	\$ 0.20
Comprehensive income (loss)	\$ 27.42	\$ 29.94	\$ 31.33	\$ 10.86	\$ 6.02	\$ (0.38)	\$ 47.87	\$ 11.81	\$ 12.45	\$ 13.17	\$ 13.91	\$ 51.34
Shares for Basic EPS (millions of shares)	94.19	96.56	103.28	103.51	102.64	102.58	103.00	102.58	102.58	102.58	102.58	102.58
Shares for Diluted EPS (millions of shares)	94.19	96.56	103.28	103.51	102.64	102.58	103.00	102.58	102.58	102.58	102.58	102.58
EPS Basic	\$ 0.42	\$ 0.48	\$ 0.21	\$ 0.02	\$ 0.12	\$ 0.14	\$ 0.50	\$ 0.12	\$ 0.12	\$ 0.13	\$ 0.14	\$ 0.50
EPS Diluted	\$ 0.42	\$ 0.48	\$ 0.21	\$ 0.02	\$ 0.12	\$ 0.14	\$ 0.50	\$ 0.12	\$ 0.12	\$ 0.13	\$ 0.14	\$ 0.50
GAAP Earnings Growth	N/A	14.3%	5.4%	-88.1%	316.4%	117.6%	3.5%	-45.0%	420.1%	3.2%	-1.7%	1.1%

N/A – Data not currently available

SBC Medical Group Holdings, Inc.
 Nasdaq: SBC
 Quarterly EBITDA
 \$ in Millions

	2023 Actual	2024 Actual	2025 Actual				2026 Estimated					
	Fiscal 2023A	Fiscal 2024A	1QA Mar-25	2QA Jun-25	3QA Sep-25	4QA Dec-25	Fiscal 2025A	1QE Mar-26	2QE Jun-26	3QE Sep-26	4QE Dec-26	Fiscal 2026E
Operating Profit	\$ 39.37	\$ 70.30	\$ 24.20	\$ 14.56	\$ 15.88	\$ 12.85	\$ 67.49	\$ 17.32	\$ 18.30	\$ 19.31	\$ 20.34	\$ 75.27
Interest expense	\$ -	\$ 0.03	\$ 0.01	\$ 0.03	\$ 0.05	\$ 0.06	\$ 0.14	\$ 0.06	\$ 0.06	\$ 0.06	\$ 0.06	\$ 0.22
Depreciation, depletion & amortization	\$ 12.25	\$ 3.80	\$ 0.67	\$ 0.67	\$ 0.67	\$ 0.67	\$ 2.68	\$ 0.67	\$ 0.67	\$ 0.67	\$ 0.67	\$ 2.67
EBITDA	\$ 51.62	\$ 74.13	\$ 24.88	\$ 15.25	\$ 16.60	\$ 13.58	\$ 70.31	\$ 18.04	\$ 19.02	\$ 20.03	\$ 21.07	\$ 78.16
EBITDA Margin (%)	26.7%	36.1%	52.6%	35.2%	38.3%	34.3%	40.5%	41.5%	42.4%	43.4%	44.3%	42.9%
Impairment of goodwill	\$ -	\$ 15.06	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain on disposal of assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of other long-lived assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Inventory obsolescence charges	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Acquisition related costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Public offering costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Stock based compensation	\$ -	\$ 13.02	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other income, net	\$ -	\$ (3.18)	\$ (7.26)	\$ 0.99	\$ (2.67)	\$ (5.78)	\$ (14.72)	\$ (2.63)	\$ (2.72)	\$ (2.91)	\$ (3.12)	\$ (11.38)
Interest on trade accounts receivable	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Adjusted EBITDA	\$ 51.62	\$ 99.03	\$ 17.62	\$ 16.24	\$ 13.93	\$ 7.80	\$ 55.59	\$ 15.41	\$ 16.30	\$ 17.12	\$ 17.95	\$ 66.77
Adjusted EBITDA Margin (%)	26.7%	48.2%	37.2%	37.5%	32.1%	19.7%	32.0%	35.4%	36.4%	37.1%	37.7%	36.7%

SBC Medical Group Holdings, Inc.
 Nasdaq: SBC
Cash Flow Statement
 \$ in Millions

	2023 Actual	2024 Actual	2025 Actual					2026 Estimated				
	Fiscal	Fiscal	1QA	2QA	3QA	4QA	Fiscal	1QE	2QE	3QE	4QE	Fiscal
	2023A	2024A	Mar-25	Jun-25	Sep-25	Dec-25	2025A	Mar-26	Jun-26	Sep-26	Dec-26	2026E
Net income	\$ 38.56	\$ 46.69	\$ 21.49	\$ 2.44	\$ 12.83	\$ 14.28	\$ 51.05	\$ 11.86	\$ 12.50	\$ 13.22	\$ 13.96	\$ 51.54
Stock-based compensation	\$ -	\$ 13.02	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Depreciation, depletion and amortization	\$ 12.25	\$ 3.80	\$ 0.63	\$ 0.64	\$ 0.75	\$ 0.67	\$ 2.68	\$ 0.67	\$ 0.67	\$ 0.67	\$ 0.67	\$ 2.69
Amortization of debt origination costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Bad debt expense	\$ 0.37	\$ (0.40)	\$ 0.03	\$ 0.26	\$ 0.02	\$ (0.00)	\$ 0.30	\$ -	\$ -	\$ -	\$ -	\$ -
Gain/(loss) on disposal of property and equipment	\$ (0.25)	\$ 0.51	\$ (0.01)	\$ 0.00	\$ (0.40)	\$ (2.77)	\$ (3.18)	\$ -	\$ -	\$ -	\$ -	\$ -
Gain from sale of equipment damaged or lost	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of goodwill	\$ -	\$ 15.06	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Gain on sale of business	\$ -	\$ (3.81)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Impairment of other long-lived assets	\$ 0.20	\$ 0.53	\$ -	\$ -	\$ -	\$ 0.13	\$ 0.13	\$ -	\$ -	\$ -	\$ -	\$ -
Deferred income taxes	\$ 4.11	\$ (14.42)	\$ 7.02	\$ 0.44	\$ 1.65	\$ (3.77)	\$ 5.33	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 3.08	\$ 6.49	\$ (7.62)	\$ 1.33	\$ 0.11	\$ 1.07	\$ (5.11)	\$ -	\$ -	\$ -	\$ -	\$ -
Subtotal	\$ 58.32	\$ 67.47	\$ 21.53	\$ 5.11	\$ 14.96	\$ 9.61	\$ 51.21	\$ 12.53	\$ 13.17	\$ 13.89	\$ 14.64	\$ 54.23
Accounts receivable, net - decrease (increase)	\$ (0.60)	\$ 17.74	\$ (0.15)	\$ (0.64)	\$ (0.29)	\$ 16.74	\$ 15.66	\$ -	\$ -	\$ -	\$ -	\$ -
Receivables from related parties - decrease (increase)	\$ (5.41)	\$ (4.64)	\$ (0.30)	\$ (15.14)	\$ (9.67)	\$ 13.91	\$ (11.20)	\$ -	\$ -	\$ -	\$ -	\$ -
Inventories - decrease (increase)	\$ (1.83)	\$ 1.13	\$ 1.60	\$ (2.32)	\$ 0.98	\$ (0.44)	\$ (0.17)	\$ -	\$ -	\$ -	\$ -	\$ -
Pre-paid expenses and other assets - decrease (increase)	\$ (0.77)	\$ (2.05)	\$ (3.15)	\$ 2.10	\$ (0.77)	\$ 2.47	\$ 0.65	\$ -	\$ -	\$ -	\$ -	\$ -
Accounts payable - decrease (increase)	\$ 12.18	\$ (9.59)	\$ 3.24	\$ (4.65)	\$ 3.96	\$ 0.13	\$ 2.68	\$ -	\$ -	\$ -	\$ -	\$ -
Payables to related parties - decrease (increase)	\$ -	\$ (34.08)	\$ (0.11)	\$ 0.11	\$ (10.62)	\$ 4.53	\$ (6.09)	\$ -	\$ -	\$ -	\$ -	\$ -
Accrued expenses and other liabilities - decrease (increase)	\$ (24.59)	\$ (26.63)	\$ (3.10)	\$ (4.51)	\$ (5.53)	\$ (3.25)	\$ (16.39)	\$ -	\$ -	\$ -	\$ -	\$ -
Income taxes payable - decrease (increase)	\$ 13.36	\$ 11.23	\$ (17.64)	\$ 11.60	\$ (13.91)	\$ 8.27	\$ (11.66)	\$ -	\$ -	\$ -	\$ -	\$ -
Operating Activities - Net Cash Flow	\$ 50.67	\$ 20.58	\$ 1.93	\$ (8.34)	\$ (20.88)	\$ 51.98	\$ 24.67	\$ 12.53	\$ 13.17	\$ 13.89	\$ 14.64	\$ 54.23
Purchases of property and equipment	\$ (10.23)	\$ (3.41)	\$ (0.76)	\$ (0.51)	\$ (0.18)	\$ (0.93)	\$ (2.37)	\$ (0.93)	\$ (0.93)	\$ (0.93)	\$ (0.93)	\$ (3.71)
Business divestitures, net of cash transferred	\$ 0.72	\$ (5.07)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Acquisition, net of cash	\$ -	\$ -	\$ -	\$ -	\$ (14.86)	\$ (28.14)	\$ (43.01)	\$ -	\$ -	\$ -	\$ -	\$ -
Purchases of property and equipment from related parties	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Contributions to others	\$ (1.70)	\$ 0.41	\$ 0.09	\$ 15.50	\$ 2.28	\$ 0.03	\$ 17.89	\$ -	\$ -	\$ -	\$ -	\$ -
Proceeds from disposal of property and equipment	\$ 8.05	\$ -	\$ 0.32	\$ 1.41	\$ 1.03	\$ 4.72	\$ 7.48	\$ -	\$ -	\$ -	\$ -	\$ -
Purchase of investments	\$ 4.95	\$ (2.03)	\$ (0.64)	\$ (0.02)	\$ (0.43)	\$ 0.11	\$ (0.97)	\$ -	\$ -	\$ -	\$ -	\$ -
Investing Activities - Net Cash Flow	\$ 1.79	\$ (10.10)	\$ (0.98)	\$ 16.38	\$ (12.16)	\$ (24.22)	\$ (20.97)	\$ (0.93)	\$ (0.93)	\$ (0.93)	\$ (0.93)	\$ (3.71)
Borrowings on long-term debt	\$ -	\$ 6.60	\$ -	\$ -	\$ 14.85	\$ 19.90	\$ 34.75	\$ -	\$ -	\$ -	\$ -	\$ -
Borrowings on long-term debt - related parties	\$ 12.31	\$ 5.48	\$ 0.02	\$ -	\$ -	\$ -	\$ 0.02	\$ -	\$ -	\$ -	\$ -	\$ -
Repayments of long-term debt	\$ (16.44)	\$ (0.86)	\$ (0.06)	\$ (0.05)	\$ (0.62)	\$ (0.63)	\$ (1.35)	\$ -	\$ -	\$ -	\$ -	\$ -
Proceeds from financing transaction	\$ 0.00	\$ 11.74	\$ -	\$ -	\$ (5.00)	\$ -	\$ (5.00)	\$ -	\$ -	\$ -	\$ -	\$ -
Proceeds from sale/leaseback transaction	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Payments on sale/leaseback transaction	\$ -	\$ -	\$ (0.22)	\$ (0.06)	\$ 0.28	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Dividends paid	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Principal payments on financing leases/notes	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (0.33)	\$ (0.33)	\$ -	\$ -	\$ -	\$ -	\$ -
Debt issuance costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other	\$ 10.26	\$ -	\$ (0.02)	\$ 7.28	\$ 2.06	\$ 0.88	\$ 10.20	\$ -	\$ -	\$ -	\$ -	\$ -
Financing Activities - Net Cash Flow	\$ 6.14	\$ 22.97	\$ (0.28)	\$ 7.18	\$ 11.57	\$ 19.82	\$ 38.29	\$ -	\$ -	\$ -	\$ -	\$ -
Exchange rate effect	\$ (7.31)	\$ (11.43)	\$ 6.34	\$ 5.47	\$ (3.84)	\$ (11.23)	\$ (3.26)	\$ -	\$ -	\$ -	\$ -	\$ -
Cash and Equivalents - Change	\$ 51.28	\$ 22.02	\$ 7.01	\$ 20.68	\$ (25.31)	\$ 36.34	\$ 38.73	\$ 11.60	\$ 12.24	\$ 12.96	\$ 13.71	\$ 50.52
Cash Beginning	\$ 51.74	\$ 103.02	\$ 125.04	\$ 132.06	\$ 152.74	\$ 127.43	\$ 125.04	\$ 163.77	\$ 175.37	\$ 187.62	\$ 200.58	\$ 163.77
Cash End	\$ 103.02	\$ 125.04	\$ 132.06	\$ 152.74	\$ 127.43	\$ 163.77	\$ 163.77	\$ 175.37	\$ 187.62	\$ 200.58	\$ 214.29	\$ 214.29

SBC Medical Group Holdings, Inc.
 Nasdaq: SBC
 Balance Sheet
 \$ in Millions

	2023 Actual	2024 Actual	2025 Actual					2026 Estimated				
	Fiscal 2023A	Fiscal 2024A	1QA Mar-25	2QA Jun-25	3QA Sep-25	4QA Dec-25	Fiscal 2025A	1QE Mar-26	2QE Jun-26	3QE Sep-26	4QE Dec-26	Fiscal 2026E
Cash & equivalents	\$ 103.02	\$ 125.04	\$ 132.06	\$ 152.74	\$ 127.43	\$ 163.77	\$ 163.77	\$ 175.37	\$ 187.62	\$ 200.58	\$ 214.29	\$ 214.29
Short term investments	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 0.32	\$ 0.32	\$ -	\$ -	\$ -	\$ -	\$ -
Restricted Cash	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Accounts receivable, net	\$ 1.44	\$ 1.41	\$ 1.63	\$ 2.35	\$ 2.61	\$ 2.39	\$ 2.39	\$ 2.51	\$ 2.51	\$ 2.51	\$ 2.51	\$ 2.51
Receivables from related parties, net	\$ 48.31	\$ 45.22	\$ 46.74	\$ 70.49	\$ 79.94	\$ 49.05	\$ 49.05	\$ 50.28	\$ 50.28	\$ 50.28	\$ 50.28	\$ 50.28
Inventories	\$ 3.09	\$ 1.50	\$ 1.70	\$ 1.71	\$ 1.68	\$ 2.79	\$ 2.79	\$ 2.86	\$ 2.86	\$ 2.86	\$ 2.86	\$ 2.86
Pre-paid expenses	\$ 10.05	\$ 11.28	\$ 32.97	\$ 14.05	\$ 14.71	\$ 11.72	\$ 11.72	\$ 12.01	\$ 12.01	\$ 12.01	\$ 12.01	\$ 12.01
Other current assets	\$ -	\$ -	\$ -	\$ -	\$ 0.84	\$ 1.18	\$ 1.18	\$ 1.18	\$ 1.18	\$ 1.18	\$ 1.18	\$ 1.18
Total Current Assets	\$ 165.91	\$ 184.45	\$ 215.10	\$ 241.34	\$ 227.20	\$ 231.22	\$ 231.22	\$ 244.21	\$ 256.45	\$ 269.42	\$ 283.13	\$ 283.13
Property & equipment, net	\$ 13.58	\$ 8.77	\$ 8.52	\$ 8.06	\$ 7.00	\$ 7.54	\$ 7.54	\$ 7.54	\$ 7.54	\$ 7.54	\$ 7.54	\$ 7.54
Operating lease right-of-use assets	\$ 5.92	\$ 5.27	\$ 5.15	\$ 5.15	\$ 4.89	\$ 8.37	\$ 8.37	\$ 8.37	\$ 8.37	\$ 8.37	\$ 8.37	\$ 8.37
Intangible assets, net - customer relationships	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Intangible assets, net	\$ 19.74	\$ 1.59	\$ 1.54	\$ 1.59	\$ 23.30	\$ 47.74	\$ 47.74	\$ 47.74	\$ 47.74	\$ 47.74	\$ 47.74	\$ 47.74
Goodwill	\$ 3.59	\$ 4.61	\$ 4.78	\$ 5.01	\$ 4.93	\$ 15.43	\$ 15.43	\$ 15.43	\$ 15.43	\$ 15.43	\$ 15.43	\$ 15.43
Deferred income tax asset	\$ -	\$ -	\$ -	\$ 2.34	\$ 0.61	\$ 4.01	\$ 4.01	\$ 4.01	\$ 4.01	\$ 4.01	\$ 4.01	\$ 4.01
Other non-current assets	\$ 50.07	\$ 51.59	\$ 49.51	\$ 51.81	\$ 53.44	\$ 66.14	\$ 66.14	\$ 66.14	\$ 66.14	\$ 66.14	\$ 66.14	\$ 66.14
TOTAL ASSETS	\$ 258.81	\$ 266.09	\$ 284.61	\$ 315.30	\$ 321.36	\$ 380.45	\$ 380.45	\$ 393.44	\$ 405.68	\$ 418.65	\$ 432.36	\$ 432.36
Accounts payable	\$ 26.53	\$ 13.88	\$ 17.85	\$ 16.29	\$ 17.26	\$ 16.99	\$ 16.99	\$ 17.69	\$ 17.69	\$ 17.69	\$ 17.69	\$ 17.69
Payables to related parties	\$ 3.37	\$ 0.69	\$ 2.57	\$ 9.33	\$ 4.48	\$ 0.65	\$ 0.65	\$ 0.67	\$ 0.67	\$ 0.67	\$ 0.67	\$ 0.67
Accrued expenses & other current liabilities	\$ 26.67	\$ 11.75	\$ 8.56	\$ 6.74	\$ 7.99	\$ 15.65	\$ 15.65	\$ 16.04	\$ 16.04	\$ 16.04	\$ 16.04	\$ 16.04
Accrued expenses & other current liab/related parties	\$ 23.06	\$ 11.74	\$ 13.50	\$ 10.33	\$ 7.35	\$ 5.36	\$ 5.36	\$ 5.49	\$ 5.49	\$ 5.49	\$ 5.49	\$ 5.49
Current operating lease liability	\$ 3.89	\$ 4.34	\$ 4.29	\$ 3.79	\$ 3.69	\$ 4.55	\$ 4.55	\$ 4.55	\$ 4.55	\$ 4.55	\$ 4.55	\$ 4.55
Current portion of long term debt	\$ 0.16	\$ 0.10	\$ 0.07	\$ 0.07	\$ 3.04	\$ 9.10	\$ 9.10	\$ 9.10	\$ 9.10	\$ 9.10	\$ 9.10	\$ 9.10
Income taxes payable	\$ 8.78	\$ 18.71	\$ 1.62	\$ 14.13	\$ 0.77	\$ 8.82	\$ 8.82	\$ 9.04	\$ 9.04	\$ 9.04	\$ 9.04	\$ 9.04
Total Current Liabilities	\$ 92.45	\$ 61.19	\$ 48.47	\$ 60.68	\$ 44.58	\$ 61.12	\$ 61.12	\$ 62.58	\$ 62.58	\$ 62.58	\$ 62.58	\$ 62.58
Long-term debt (revolver), net of current portion	\$ 1.06	\$ 6.50	\$ 6.80	\$ 7.03	\$ 18.08	\$ 33.73	\$ 33.73	\$ 33.73	\$ 33.73	\$ 33.73	\$ 33.73	\$ 33.73
Long-term debt from related parties	\$ 11.95	\$ 0.01	\$ 0.01	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Deferred income tax liability	\$ 6.01	\$ 0.93	\$ 0.35	\$ 0.35	\$ 7.77	\$ 16.37	\$ 16.37	\$ 16.37	\$ 16.37	\$ 16.37	\$ 16.37	\$ 16.37
Long-term operating lease liability	\$ 2.44	\$ 1.24	\$ 1.51	\$ 1.37	\$ 1.70	\$ 4.25	\$ 4.25	\$ 4.25	\$ 4.25	\$ 4.25	\$ 4.25	\$ 4.25
Asset retirement obligations	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other long-term liabilities	\$ 1.08	\$ 1.19	\$ 1.15	\$ 1.21	\$ 1.17	\$ 1.66	\$ 1.66	\$ 1.66	\$ 1.66	\$ 1.66	\$ 1.66	\$ 1.66
TOTAL LIABILITIES	\$ 115.00	\$ 71.06	\$ 58.28	\$ 70.65	\$ 73.30	\$ 117.14	\$ 117.14	\$ 118.60	\$ 118.60	\$ 118.60	\$ 118.60	\$ 118.60
Common stock	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01	\$ 0.01
Additional paid-in capital	\$ 36.88	\$ 62.51	\$ 62.51	\$ 72.21	\$ 72.20	\$ 72.87	\$ 72.87	\$ 72.87	\$ 72.87	\$ 72.87	\$ 72.87	\$ 72.87
Retained earnings	\$ 142.85	\$ 189.46	\$ 210.97	\$ 213.41	\$ 226.25	\$ 240.46	\$ 240.46	\$ 252.00	\$ 264.23	\$ 277.20	\$ 290.91	\$ 290.91
Accumulated comprehensive income/(loss)	\$ (37.58)	\$ (54.18)	\$ (44.34)	\$ (35.92)	\$ (42.72)	\$ (57.29)	\$ (57.29)	\$ (57.29)	\$ (57.29)	\$ (57.29)	\$ (57.29)	\$ (57.29)
Non-controlling interest	\$ 1.65	\$ (0.09)	\$ (0.12)	\$ 0.06	\$ 0.07	\$ 15.00	\$ 15.00	\$ 15.00	\$ 15.00	\$ 15.00	\$ 15.00	\$ 15.00
Less: treasury stock	\$ -	\$ (2.70)	\$ (2.70)	\$ (5.12)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)	\$ (7.75)
TOTAL EQUITY	\$ 143.81	\$ 195.02	\$ 226.32	\$ 244.65	\$ 248.06	\$ 263.30	\$ 263.30	\$ 274.84	\$ 287.08	\$ 300.05	\$ 313.75	\$ 313.75
TOTAL LIABILITIES & EQUITY	\$ 258.81	\$ 266.09	\$ 284.61	\$ 315.30	\$ 321.36	\$ 380.45	\$ 380.45	\$ 393.44	\$ 405.68	\$ 418.65	\$ 432.35	\$ 432.35

SBC Medical Group Holdings, Inc.
Nasdaq: SBC
Discounted Cash Flow Model (DCF)
 (\$ in millions, except per share)

Estimates:	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E	Terminal Value
Revenue	\$ 182.08	\$ 204.84	\$ 228.39	\$ 252.38	\$ 276.35	\$ 299.84	\$ 322.33	\$ 343.28	\$ 340.06	\$ 358.73	
Operating Income	\$ 75.27	\$ 81.93	\$ 91.36	\$ 100.95	\$ 110.54	\$ 119.94	\$ 128.93	\$ 137.31	\$ 136.02	\$ 143.49	
Less: Taxes (benefit)	\$ 34.57	\$ 32.77	\$ 36.54	\$ 40.38	\$ 44.22	\$ 47.97	\$ 51.57	\$ 54.92	\$ 54.41	\$ 57.40	
NOPAT	\$ 40.70	\$ 49.16	\$ 54.81	\$ 60.57	\$ 66.32	\$ 71.96	\$ 77.36	\$ 82.39	\$ 81.61	\$ 86.09	
Add: Depreciation & Amortization	\$ 2.69	\$ 2.56	\$ 2.43	\$ 2.78	\$ 3.04	\$ 3.30	\$ 3.55	\$ 3.78	\$ 3.74	\$ 3.95	
Add: Changes in NWC	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Less: Capital Expenditures	\$ 3.71	\$ 2.56	\$ 2.85	\$ 3.15	\$ 3.45	\$ 3.75	\$ 4.03	\$ 4.29	\$ 4.25	\$ 4.48	
Free Cash Flow	\$ 39.68	\$ 49.16	\$ 54.39	\$ 60.19	\$ 65.91	\$ 71.51	\$ 76.88	\$ 81.87	\$ 81.10	\$ 85.56	\$ 1,151.91
Discount Period - Months	9.00	21.00	33.00	45.00	57.00	69.00	81.00	93.00	93.00	105.00	105.00
Discount Period - Years	0.75	1.75	2.75	3.75	4.75	5.75	6.75	7.75	7.75	8.75	8.75
Discount Factor	0.93	0.84	0.76	0.68	0.62	0.56	0.51	0.46	0.46	0.41	0.41
Present Value of FCF	\$ 36.78	\$ 41.18	\$ 41.18	\$ 41.18	\$ 40.75	\$ 39.96	\$ 38.82	\$ 37.37	\$ 37.02	\$ 35.29	\$ 475.16

Growth Rate Assumptions:

Revenue (1% stepdown/year)	12.5%
Terminal Growth Rate (g):	3.0%
Discount Rate at WACC:	10.7%

Margin Assumptions:

Operating Income	40.0%
D&A as a % of sales (long-term)	1.1%
Taxes	40.0%
Changes in WC	0.0%
Capex as a % of sales	1.3%

Valuation:

Shares Outstanding	102.58
PV of FCF	\$ 389.54
PV of Terminal Value	\$ 475.16
Enterprise Value	\$ 864.70
less: Net Debt (Q4:25)	(120.94)
less: Minority Interest (Q4:25)	\$ 15.00
Estimated Total Value	\$ 970.64
Est. Equity Value per Share	\$ 9.46

Price Target Sensitivity Analysis:

Discount Rate		Terminal Growth Rate (g)				
		1.0%	2.0%	3.0%	4.0%	5.0%
10.0%	10.0%	9.01	9.56	10.27	11.22	12.55
	10.5%	8.56	9.03	9.64	10.43	11.50
	11.0%	8.15	8.56	9.08	9.74	10.63
	11.5%	7.78	8.14	8.59	9.15	9.89
	12.0%	7.45	7.77	8.15	8.63	9.25